PHOENIX, July 26, 2018 (GLOBE NEWSWIRE) — Dennis Calvert, CEO of BioLargo, Inc. (BLGO) recently spoke with “Stock Day” Podcast host Everett Jolly about BioLargo’s progress since the previous show at the end of May.
BioLargo is a sustainable technology incubator and environmental engineering company that develops innovative technology solutions for clean air, clean water, and advanced wound care. Jolly started the interview by stating that he believes the company is “ready to blow up” in growth and that the company is undervalued at $0.33.
Jolly started the interview by asking Calvert to give an update on the company’s first commercial success, CupriDyne Clean®, its odor and VOC control product being sold to the waste management industry and wastewater treatment industry. Calvert responded that CupriDyne Clean has become recognized as the number one performing product in the market and is being offered at value pricing, saving clients 25 – 50% per month. He explained that BioLargo is doing business with all the major players in the US waste handling industry. He explained that they are gaining traction with its national accounts through a regional adoption process and that it has won business with a number of flagship municipal wastewater treatment operators. Calvert explained that they now offer a turn-key solution where they design, build, install, maintain, and service odor control delivery systems utilizing CupriDyne Clean that can tackle what some consider the industry’s Achilles’ heel – odor control. Continued expansion is planned by scaling up operations to meet customer demand.
Jolly then asked Calvert for an update about Clyra Medical and its process with the FDA. Calvert responded that Clyra has a product being reviewed by the FDA within the 90-day time frame. He explained that the application is about halfway through the process, all the data is assembled, and the team is confident in the product and the success of their application process.
Jolly closed by asking about the commercialization of the AOS, which was discussed in the previous show. Calvert explained that management is confident it had solved the scale-up challenges and the company has four pilots either in progress or planned to begin in the Fall of 2018 and how critical data from this work would be used to support the AOS’ commercial value proposition in terms of performance, low capital cost, and low operating cost.
For more information about BioLargo’s marketing strategies, product updates, pending FDA approvals, and the company’s systematic adoption strategies, listen to the full interview at the link below.
For up-to-date information on the company’s technologies and products, follow their blog at the link below:
About BioLargo, Inc.
BioLargo, Inc., is an innovative technology incubator and environmental engineering company driven by a mission to “make life better” by delivering robust, sustainable solutions for a broad range of industries and applications, with a focus on clean water, clean air, and advanced wound care. We incubate disruptive technologies by providing the capital, support, and expertise to expedite them from “cradle” to “maturity” (www.biolargo.com). Our engineering division features experienced professional engineers dedicated to integrity, reliability, and environmental stewardship (www.biolargoengineering.com). Our industrial odor control division, Odor-No-More (www.odornomore.com) features CupriDyne Clean Industrial Odor Eliminator (www.cupridyne.com), which eliminates the odor-causing compounds and VOCs rather than masking them, and is now winning over leading companies in the solid waste handling and wastewater industries and other industries that contend with malodors and VOCs. Our subsidiary BioLargo Water (www.biolargowater.ca) develops the Advanced Oxidation System (“AOS”), a disruptive industrial water treatment technology designed to eliminate waterborne pathogens and recalcitrant contaminants with better energy efficiency and lower operational costs than incumbent technologies. Our subsidiary Clyra Medical (www.clyramedical.com) features effective and gentle solutions for chronic infected wounds to promote infection control and regenerative tissue therapy.